^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    M9466

    i
    Other names: M9466, HRS-1167, HRS1167, M 9466, HRS 1167, M-9466
    Associations

    News

    Trials
    Company:
    EMD Serono, Jiangsu Hengrui Pharma
    Drug class:
    PARP1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    16d
    A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer (clinicaltrials.gov)
    P1/2, N=100, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Trial completion date: Dec 2026 --> Jun 2027 | Trial primary completion date: Sep 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    docetaxel • abiraterone acetate • prednisone • zeprumetostat (SHR-2554) • HRS-5041 • M9466
    4ms
    M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501) (clinicaltrials.gov)
    P1, N=141, Recruiting, EMD Serono Research & Development Institute, Inc. | N=96 --> 141 | Trial completion date: Mar 2026 --> Feb 2027 | Trial primary completion date: Mar 2026 --> Feb 2027
    Enrollment change • Trial completion date • Trial primary completion date
    |
    abiraterone acetate • prednisone • tuvusertib (M1774) • M9466 • prednisolone
    6ms
    Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521) (clinicaltrials.gov)
    P1, N=0, Withdrawn, EMD Serono Research & Development Institute, Inc. | N=54 --> 0 | Trial completion date: Oct 2027 --> May 2025 | Not yet recruiting --> Withdrawn | Trial primary completion date: Oct 2027 --> May 2025
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • M9466
    8ms
    Study of HRS-1167 as Monotherapy in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=153, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    HRD (Homologous Recombination Deficiency)
    |
    M9466
    9ms
    Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521) (clinicaltrials.gov)
    P1, N=54, Not yet recruiting, EMD Serono Research & Development Institute, Inc. | Initiation date: Jan 2025 --> Jul 2025
    Trial initiation date
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • M9466
    9ms
    M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511) (clinicaltrials.gov)
    P1, N=54, Suspended, EMD Serono Research & Development Institute, Inc. | Recruiting --> Suspended
    Trial suspension
    |
    Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • M9466
    11ms
    A Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone (clinicaltrials.gov)
    P1/2, N=66, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    abiraterone acetate • prednisone • M9466
    12ms
    Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab (clinicaltrials.gov)
    P2, N=130, Recruiting, Fudan University | Not yet recruiting --> Recruiting | Initiation date: Jul 2024 --> Sep 2024
    Enrollment open • Trial initiation date • IO biomarker
    |
    BRCA (Breast cancer early onset)
    |
    AiRuiKa (camrelizumab) • famitinib (SHR 1020) • M9466
    12ms
    Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521) (clinicaltrials.gov)
    P1, N=54, Not yet recruiting, EMD Serono Research & Development Institute, Inc.
    New P1 trial • Combination therapy
    |
    Tecentriq (atezolizumab) • carboplatin • etoposide IV • M9466
    1year
    A Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone (clinicaltrials.gov)
    P1/2, N=66, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.
    New P1/2 trial
    |
    abiraterone acetate • prednisone • M9466
    1year
    M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511) (clinicaltrials.gov)
    P1, N=54, Recruiting, EMD Serono Research & Development Institute, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • M9466
    1year
    A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer (clinicaltrials.gov)
    P1/2, N=100, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    docetaxel • abiraterone acetate • prednisone • zeprumetostat (SHR-2554) • HRS-5041 • M9466